Search
SMART101
go.drugbank.com/drugs/DB18370InvestigationalSMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.
RAPA-201
go.drugbank.com/drugs/DB18446InvestigationalRAPA-201 is an autologous rapamycin-resistant T-cell therapy.
Synonyms: Rapamycin-resistant autologous Th1/Tc1 T-cellsASP-2138
go.drugbank.com/drugs/DB18473InvestigationalASP-2138 is a bispecific antibody directed against CLDN18.2 and T cell receptor complex CD3
CTX130
go.drugbank.com/drugs/DB18627InvestigationalCTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Synonyms: Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD70 antigenALLO-605
go.drugbank.com/drugs/DB18641InvestigationalALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).
ATIR101
go.drugbank.com/drugs/DB18650InvestigationalATIR101 is a haploidentical, naïve cell-enriched T-cell therapy.
ssCART-19 cells
go.drugbank.com/drugs/DB18653InvestigationalssCART-19 cells consist of autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6).
Synonyms: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)Geptanolimab
go.drugbank.com/drugs/DB16417InvestigationalGeptanolimab is under investigation in clinical trial NCT03502629 (Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)).
Etentamig
go.drugbank.com/drugs/DB17268InvestigationalTNB-383B is a CD3 and B-cell maturation antigen T-cell engaging bispecific antibody.
Synonyms: Anti-BCMA x aCD3 T-BsAb TNB-383B, Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383AMG-119
go.drugbank.com/drugs/DB17363InvestigationalAMG-119 are CAR-T cells targeting delta-like ligand 3 (DLL3).[A254811]